Unique ID issued by UMIN | UMIN000058498 |
---|---|
Receipt number | R000066869 |
Scientific Title | Clinical Efficacy of Sunekos Therapy for the Face: A Self-Controlled Prospective Evaluation |
Date of disclosure of the study information | 2025/07/17 |
Last modified on | 2025/07/17 11:37:03 |
Clinical Efficacy of Sunekos Therapy for the Face: A Self-Controlled Prospective Evaluation
Clinical Efficacy of Sunekos Therapy for the Face: A Self-Controlled Prospective Evaluation
Clinical Efficacy of Sunekos Therapy for the Face: A Self-Controlled Prospective Evaluation
Clinical Efficacy of Sunekos Therapy for the Face: A Self-Controlled Prospective Evaluation
Japan |
Skin tissue that has atrophied or changed due to aging, trauma, congenital etc.
Dermatology | Aesthetic surgery | Adult |
Others
NO
This study will use a prospective survey based on patient data to examine the effectiveness of Snekos treatment on skin tissue that has atrophied or been deformed due to aging, trauma, congenital conditions, etc.
Efficacy
Take pictures at baseline (before treatment), and at 2 weeks and 1 month after the injection. A patient-reported outcome assessment will be conducted 1 month post-injection.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Self control
1
Treatment
Medicine |
The injection will be administered separately to each side of the face as follows:
Right side: SUNEKOS
Left side: Normal saline
The injection method will be water-light injection (mesotherapy), targeting the dermal layer.
The total injection volume will be 3 mL.
30 | years-old | <= |
39 | years-old | > |
Male and Female
Individuals who meet all of the following criteria:
who have clear tissue deformity or atrophy due to congenital conditions, trauma, or aging.
who are expected to benefit from this treatment.
who wish to receive the treatment and have been deemed suitable for it by a physician.
who are able to attend outpatient visits.
who are adults.
who have provided written informed consent for this treatment.
who have insufficient understanding of this treatment.
who lack the capacity to make an appropriate decision regarding this treatment.
who do not wish to receive this treatment or for whom obtaining consent is difficult.
Who are deemed unsuitable by the physician.
10
1st name | Hiroo |
Middle name | |
Last name | Teranishi |
Tokyo Chuo Beauty Clinic (TCB), BS Clinic, Umeda Osaka Ekimae Branch
Director
5300057
3rd Floor, K's Square Building, 2-8-15 Sonezaki, Kita-ku, Osaka-city, Osaka, Japan
06-6147-2581
umeda.office@cybervision21.com
1st name | Taichi |
Middle name | |
Last name | Tamura |
Tokyo Chuo Beauty Clinic (TCB), BS Clinic, Umeda Osaka Ekimae Branch
Tokyo Chuo Beauty Clinic (TCB), BS Clinic, Umeda Osaka Ekimae Branch
5300057
3rd Floor, K's Square Building, 2-8-15 Sonezaki, Kita-ku, Osaka-city, Osaka, Japan
06-6147-2581
dr.tamura.taichi@cybervision21.com
Tokyo Chuo Beauty Clinic (TCB), BS Clinic, Umeda Osaka Ekimae Branch
None
Self funding
TCB Academic Committee and IRB
3rd Floor, K's Square Building, 2-8-15 Sonezaki, Kita-ku, Osaka-city, Osaka, Japan
06-6147-2581
irb@medical-frontier.jp
NO
2025 | Year | 07 | Month | 17 | Day |
Unpublished
Enrolling by invitation
2025 | Year | 05 | Month | 01 | Day |
2025 | Year | 04 | Month | 26 | Day |
2025 | Year | 05 | Month | 15 | Day |
2025 | Year | 07 | Month | 24 | Day |
2025 | Year | 07 | Month | 17 | Day |
2025 | Year | 07 | Month | 17 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066869